The poor prognosis and fewer treatment option is a current clinical challenge for patients
with lung adenosquamous carcinoma (ASC). The previous studies reported that tumor …

Introduction To depict the genomic landscape of Chinese early-stage lung squamous cell
carcinoma (LUSC) and investigate its correlation with tumor mutation burden (TMB), PD-L1 …

Background Lung squamous cell carcinoma (LSCC) is a major histological subtype of lung
cancer. In this study, we investigated genomic alterations in LSCC and evaluated the clinical …

Background The difference in molecular gene mutation profile, tumor mutational burden
(TMB) and their prognostic effects in lung adenocarcinoma between different ethnic groups …

Background Non-small cell lung cancer (NSCLC) is the most common type of lung cancer
and a highly heterogeneous disease with a diversity of phenotypes and genotypes in …

Background Tumor mutational burden (TMB) has been identified as one of the predictors for
the response to anti-programmed cell death-1 (anti-PD-1) antibody therapy and reported to …

Lung squamous cell carcinoma (LUSC) is a common type of lung cancer with high incidence
and mortality rate. Tumor mutational burden (TMB) is an emerging biomarker for selecting …

Adenosquamous carcinoma (ASC) of the lung is a relatively rare tumor with strong
aggressiveness and poor prognosis. The analysis of mutational signatures is becoming …

Background Despite considerable recent progress in the treatment of lung adenocarcinoma,
there has been little progress in the development of efficacious molecular targeted therapies …

Purpose TMB is one of the potent biomarkers of response to immune checkpoint blockade.
The association between TMB and efficacy of chemotherapy in advanced lung cancer has …